Market Dynamics:

The global major depressive disorder market is poised to exhibit a consistent revenue Compound Annual Growth Rate (CAGR) throughout the forecast period. Key drivers propelling revenue growth in the market include the increasing prevalence of major depressive disorder and shifts in lifestyle.

Factors Supporting Revenue Growth of the Market:

Primary Factors Driving Revenue Growth of the Global Major Depressive Disorder Market:

  1. Escalating Prevalence of Major Depressive Disorder: According to data from the National Library of Medicine, the prevalence of major depressive disorder varies from 2% to 21%, with some European countries reporting the highest rates and certain Asian nations reporting the lowest. Research consistently links MDD to factors such as child abuse, intimate partner violence, and comorbidity with other physical and mental illnesses.

Factors Hampering Revenue Growth of the Global Major Depressive Disorder Market:

The adverse effects associated with depression medications are expected to somewhat hinder market revenue growth, as patients may be reluctant to adopt medication therapy due to concerns and lack of awareness about the process. Side effects like nausea, impotence, anxiety, and insomnia also reduce the adoption rate of medications, restricting market revenue growth.

Depression is a mood disorder characterized by persistent feelings of sadness and a loss of interest, affecting one’s emotions, thoughts, and behaviors. It can lead to various mental and physical challenges and is also referred to as major depressive disorder or clinical depression. While some individuals may experience depression only once in their lifetime, most go through multiple episodes. Symptoms during these episodes may encompass feelings of sadness, tearfulness, emptiness, hopelessness, as well as occasional angry outbursts, irritability, or frustration, even over minor issues.

Get a sample copy of the Major Depressive Disorder Market report:

Opportunities in the Global Major Depressive Disorder Market:

Several factors offer potential opportunities for participants in the major depressive disorder market, including the need to enhance healthcare quality, the growth of domestic biotechnology sectors, availability of government research funding in emerging regions, and the development of novel diagnostic technologies.

Geographic Market Scenario:

Largest Market Share: North America is projected to secure the largest market share due to the high cost of treatment and wide availability of medications. Additionally, Europe is expected to hold the second-largest position due to the accessibility of medication, the acceptance of new treatments, advanced medicines, and innovations in treatment procedures.

Fastest Growing Region: The Asia Pacific region is anticipated to experience a steady revenue CAGR over the forecast period, driven by factors such as rising income levels and increased demand for antidepressants, fueled by the growing prevalence of anxiety disorders. Continued expansion of the healthcare sector and increasing consumer awareness in developing nations are further driving demand for treatment in this market.

Key Market Trends and Innovations:

  • On June 21, 2022, the Food and Drug Administration (FDA) authorized an extension of the Zulresso (brexanolone) drug application to include patients aged 15 and older with Postpartum Depression.

Competitive Landscape:

Adoption of Organic and Inorganic Strategies:

  • On March 30, 2022, Sun Pharma and Lundbeck signed a licensing agreement to introduce a novel antidepressant medication in India.
  • On March 28, 2022, Axsome Therapeutics acquired Sunosi from Jazz Pharmaceuticals, bolstering its leadership position in the neuroscience field.
  • On February 22, 2022, AbbVie submitted a Supplemental New Drug Application to the FDA for Cariprazine (VRAYLAR) for the Adjunctive Treatment of Major Depressive Disorder.
  • On January 7, 2022, Dr. Reddy’s Laboratories introduced Venlafaxine ER tablets in the U.S.
  • On December 20, 2021, the FDA approved CAPLYTA (lumateperone) for the treatment of adult bipolar depression, according to Intra-Cellular Therapies.
  • On June 15, 2021, New Sage Therapeutics and Biogen announced positive findings from a pivotal Phase III trial of the antidepressant zuranolone.

Major Companies in the Market Include:

  • Merck & Co.
  • GSK plc
  • AstraZeneca Plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Johnson & Johnson
  • Sanofi S.A.
  • Pfizer Inc.
  • Allergan plc
  • Lundbeck A/S
  • Alkermes


By Treatment Outlook:

  • Antidepressants (SSRIs)
  • Serotonin Norepinephrine Reuptake Inhibitor
  • Serotonin Modulators
  • Tricyclic & Tetracyclic Antidepressants
  • Atypical Antidepressants
  • Antipsychotics
  • Others

By Route of Administration Outlook:

  • Oral
  • Parenteral
  • Other

By Distribution Channel Outlook:

  • Online Channel
  • Offline Channel

By End-user Outlook:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region Outlook:

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Sweden
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Israel
    • Rest of MEA

Explore Trending Reports:

Insect Protein Market-

Dairy Testing Market-

Eggshell Membrane Market-

Food Waste Management Market-

Request a customization of the report:

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data    

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @

Browse More Latest Reports @

Browse Latest Blogs:

Browse Latest Press Release: